MDT
101.45
+0.95%↑
A
138.61
-0.74%↓
VEEV
225
+2.37%↑
HQY
86.43
+2.1%↑
NEOG
9.92
+0.61%↑
MDT
101.45
+0.95%↑
A
138.61
-0.74%↓
VEEV
225
+2.37%↑
HQY
86.43
+2.1%↑
NEOG
9.92
+0.61%↑
MDT
101.45
+0.95%↑
A
138.61
-0.74%↓
VEEV
225
+2.37%↑
HQY
86.43
+2.1%↑
NEOG
9.92
+0.61%↑
MDT
101.45
+0.95%↑
A
138.61
-0.74%↓
VEEV
225
+2.37%↑
HQY
86.43
+2.1%↑
NEOG
9.92
+0.61%↑
MDT
101.45
+0.95%↑
A
138.61
-0.74%↓
VEEV
225
+2.37%↑
HQY
86.43
+2.1%↑
NEOG
9.92
+0.61%↑
24h
Corrente
Minimo
6.04
Massimo
6.59
Entrata | 4.1M -33M |
|---|---|
Vendite | 6.1M 44M |
EPS | -3.82 |
Margine di Profitto | -75.213 |
Dipendenti | 279 |
EBITDA | 1.8M -23M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +135.29% upside |
Capitalizzazione di Mercato | 13M 116M |
|---|---|
Apertura precedente | 1.88 |
Chiusura precedente | 6.53 |
By Acuity
50%
50%
177 / 360 Classifica in Healthcare
By Trading Central
Fiducia
Bullish Evidence
5.9501 / 7.66 Supporto e resistenza
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
22 gen 2026, 21:55 UTC
Capital One Financial Posts Higher 4Q Profit As Lending Increases
DJ
LeggI
22 gen 2026, 23:52 UTC
Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update
DJ
LeggI
22 gen 2026, 23:48 UTC
Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk
DJ
LeggI
22 gen 2026, 23:42 UTC
Gold Edges Lower on Possible Profit-Taking -- Market Talk
DJ
LeggI
22 gen 2026, 23:40 UTC
Spark NZ's Market Share Loss Concerns Bear -- Market Talk
DJ
LeggI
22 gen 2026, 23:30 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
LeggI
22 gen 2026, 23:30 UTC
Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk
DJ
LeggI
22 gen 2026, 22:37 UTC
Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk
DJ
LeggI
22 gen 2026, 21:59 UTC
Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update
DJ
LeggI
22 gen 2026, 21:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
LeggI
22 gen 2026, 21:44 UTC
Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com
DJ
LeggI
22 gen 2026, 21:32 UTC
Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF
DJ
LeggI
22 gen 2026, 21:31 UTC
Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF
DJ
LeggI
22 gen 2026, 21:31 UTC
Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF
DJ
LeggI
22 gen 2026, 21:30 UTC
Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF
DJ
LeggI
22 gen 2026, 21:30 UTC
Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ
DJ
LeggI
22 gen 2026, 21:30 UTC
Capital One To Acquire Brex >COF
DJ
LeggI
22 gen 2026, 21:13 UTC
Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ
DJ
LeggI
22 gen 2026, 21:11 UTC
Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG
DJ
LeggI
22 gen 2026, 21:11 UTC
Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG
DJ
LeggI
22 gen 2026, 21:10 UTC
Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG
DJ
LeggI
22 gen 2026, 21:06 UTC
Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Provision for Credit Losses Increased $4.1B >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Rev $15.58B >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q EPS $3.26 >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Net Interest Margin 8.26% >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Net $2.13B >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Adj EPS $3.86 >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Capital One 4Q Net Charge-Offs $3.8B >COF
DJ
LeggI
22 gen 2026, 21:05 UTC
Intuitive Surgical 4Q EPS $2.21 >ISRG
DJ
LeggI
Modifica del prezzo
By TipRanks
Previsioni per 12 mesi
Media 14 USD 135.29%
Alto 19 USD
Basso 10 USD
Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By TipRanks
Fortemente da comprare
4 ratings
4
Acquista
0
Mantieni
0
Vendi
Basato sugli analisti di 4 che hanno fornito valutazioni azionarie a Karyopharm Therapeutics Inc - Dist negli ultimi 3 mesi.
By Trading Central
A breve termine
Bullish Evidence
Recent bullish events outweigh bearish events.
A termine intermedio
Strong Bearish Evidence
All events are bearish.
A lungo termine
No Evidence
There are no events.
By Acuity
Notizie sul Sentiment di mercato
Neutral
Volatilità
Sotto la media
Volume delle notizie (RCV)
Sotto la media
Spese di vendita e di amministrazione
Spese operative
Utile prima delle imposte
Vendite
Costo delle vendite
Utile lordo sulle vendite
Interessi passivi sul debito
EBITDA
Utile operativo
$